Pharma News, 2019

GARNET is the single largest study to date of an anti-PD-1 monotherapy in women with advanced or recurrent MSI-H and MSS endometrial cancer.

GeNeuro (Euronext Paris.

The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin al...

World Down Syndrome Day (also known as WDSD) is a global awareness initiative that has been backed by the United Nations since 2012.

Each year, we commemorate World Tuberculosis (TB) Day on March 24 to raise public awareness about the devastating health, social and economic consequences of TB, and to step up efforts to end ...

Milestone is part of the Flamma 2020 Plan to bring improvement across the CDMO’s network of manufacturing sites.

Servier has entered into a collaborative study with Harvard University researchers to explore a new avenue for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).

PARIS & NEW YORK--(BUSINESS WIRE)--Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited li...

CAMBRIDGE, Mass.

Sage Therapeutics' Zulresso (brexanolone) has become first treatment to be approved for post-partum depression in the US.

Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in ovarian cancer front-line maintenance setting.

Basel, 19 March 2019 - Roche (SIX.